Evolutionarily conserved pressure for the existence of distinct g2/m cell cycle arrest and a3h inactivation functions in hiv-1 vif

Cell Cycle

Volumn 14, Issue 6, 2015, Pages 838-847

  Zhao, Ke ^a   Du, Juan ^a   Rui, Yajuan ^a   Zheng, Wenwen ^a   Kang, Jian ^a   Hou, Jingwei ^a   Wang, Kang ^a   Zhang, Wenyan ^a   Simon, Viviana A ^b   Yu, Xiao Fang ^a,c  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Apobec3h; Cell cycle regulation; Evolutionary selection; Proteasomal degradation; Vif

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3H; HYDROLASE; PROTEIN VARIANT; UNCLASSIFIED DRUG; VIF PROTEIN; AMINO ACID; APOBEC3H PROTEIN, HUMAN; VIF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID ANALYSIS; ARTICLE; CELL CYCLE REGULATION; CONTROLLED STUDY; ENZYME DEGRADATION; ENZYME INACTIVATION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PROTEIN DEPLETION; AMINO ACID SEQUENCE; CHEMICAL STRUCTURE; CHEMISTRY; EVOLUTION; GENE DELETION; GENETICS; HEK293 CELL LINE; M PHASE CELL CYCLE CHECKPOINT; METABOLISM; MOLECULAR GENETICS; PROTEIN DEGRADATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID SEQUENCE; AMINO ACIDS; AMINOHYDROLASES; BIOLOGICAL EVOLUTION; G2 PHASE CELL CYCLE CHECKPOINTS; HEK293 CELLS; HIV-1; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEOLYSIS; SEQUENCE DELETION; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84928137477     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.1080/15384101.2014.1000212     Document Type: Article

References (51)

1. Fisher AG, Ensoli B, Ivanoff L, Chamberlain M, Petteway S, Ratner L, Gallo RC, Wong-Staal F. The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science 1987; 237:888-93 PMID:3497453; http://dx.doi.org/10.1126/science. 3497453
2. Strebel K, Daugherty D, Clouse K, Cohen D, Folks T, Martin MA. The HIV A (sor) gene product is essential for virus infectivity. Nature 1987; 328:728-30;PMID:2441266; http://dx.doi.org/10.1038/328728a0
3. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418:646-50; PMID:12167863; http://dx.doi.org/ 10.1038/nature00939
4. Mariani R, Chen D Schrofelbauer B, Navarro F, Konig R, Bollman B, Munk C, Nymark-McMahon H, Landau NR. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 3; 114:21-31; PMID:12859895; http://dx.doi.org/10.1016/S0092-8674(03)00515-4
5. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003; 302:1056-60;PMID:14564014; http://dx.doi. org/10.1126/science.1089591
6. Marin M, Rose KM, Kozak SL, Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 2003; 9:1398-403;PMID:14528301; http://dx.doi.org/10.1038/nm946
7. Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 2003; 9:1404-7;PMID:14528300; http://dx.doi.org/10.1038/nm945
8. Liu B, Yu X, Luo K, Yu Y, Yu XF. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J Virol 2004; 78:2072-81; PMID:14747572; http://dx.doi.org/10.1128/ JVI.78.4.2072-2081.2004
9. Kobayashi M, Takaori-Kondo A, Miyauchi Y, Iwai K, Uchiyama T. Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C complex is essential for Vif function. J Biol Chem 2005; 280:18573-8; PMID:15781449; http://dx.doi.org/ 10.1074/jbc.C500082200
10. Simon V, Zennou V, Murray D, Huang Y, Ho DD, Bieniasz PD. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathogens 2005; 1:e6; PMID:16201018; http://dx.doi.org/10.1371/journal. ppat.0010006
11. Shirakawa K, Takaori-Kondo A, Kobayashi M, Tomonaga M, Izumi T, Fukunaga K, Sasada A, Abudu A, Miyauchi Y, Akari H, et al. Ubiquitination of APOBEC3 proteins by the Vif-Cullin5-ElonginB-ElonginCcomplex. Virology 2006; 344:263-6; PMID:16303161; http://dx.doi.org/10.1016/j.virol. 2005.10.028
12. Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev 2004; 18:2867-72;PMID:15574593; http://dx.doi.org/10.1101/ gad.1250204
13. Mehle A, Goncalves J, Santa-Marta M, McPike M, Gabuzda D. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev 2004; 18:2861-6; PMID:15574592; http://dx.doi.org/ 10.1101/gad.1249904
14. Sakai H, Shibata R, Sakuragi J, Sakuragi S, Kawamura M, Adachi A. Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. J Virol 1993; 67:1663-6; PMID:8437236
15. Zhang W, Du J, Evans SL, Yu Y, Yu XF. T-cell differentiation factor CBF-b regulates HIV-1 Vif-mediated evasion of host restriction. Nature 2012; 481:376-9
16. Han X, Liang W, Hua D, Zhou X, Du J, Evans SL, Gao Q, Wang H, Viqueira R, Wei W, et al. Evolutionarily conserved requirement for core binding factor b in the assembly of the human immunodeficiency virus/ simian immunodeficiency virus Vif-cullin 5-RING E3 ubiquitin ligase. J Virol 2014; 88:3320-8; PMID:24390335; http://dx.doi.org/10.1128/JVI. 03833-13
17. Zhou X, Evans SL, Han X, Liu Y, Yu XF. Characterization of the interaction of full-length HIV-1 Vif protein with its key regulator CBFbeta and CRL5 E3 ubiquitin ligase components. PloS One 2012; 7:e33495;PMID:22479405; http://dx.doi.org/10.1371/journal. pone.0033495
18. Zhou X, Han X, Zhao K, Du J, Evans SL, Wang H, Li P, Zheng W, Rui Y, Kang J, et al. Dispersed and Conserved Hydrophobic Residues of HIV-1 Vif Are Essential for CBFbeta Recruitment and A3G Suppression. J Virol 2014; 88:2555-63;PMID:24352440; http://dx. doi.org/10.1128/JVI.03604-13
19. Guo Y, Dong L, Qiu X, Wang Y, Zhang B, Liu H, Yu Y, Zang Y, Yang M, Huang Z. Structural basis for hijacking CBF-b and CUL5 E3 ligase complex by HIV-1 Vif. Nature 2014; 505:229-33; PMID:24402281; http://dx.doi.org/10.1038/nature 12884
20. Du J, Zhao K, Rui Y, Li P, Zhou X, Zhang W, Yu XF. Differential requirements for HIV-1 Vif-mediated APOBEC3G degradation and RUNX1-mediated transcription by core binding factor b. J Virol 2013; 87:1906-11;PMID:23175372; http://dx.doi.org/10.1128/JVI.02199-12
21. Hultquist JF, McDougle RM, Anderson BD, Harris RS. HIV type 1 viral infectivity factor and the RUNX transcription factors interact with core binding factor bon genetically distinct surfaces. AIDS Res Hum Retroviruses 2012; 28:1543-51;PMID:22725134; http://dx. doi.org/10.1089/aid.2012.0142
22. Wang H, Liu B, Liu X, Li Z, Yu X-F, ZhangW. Identification of HIV-1 Vif Regions Required for CBF-b Interaction and APOBEC3 Suppression. PloS One 2014; 9:e95738;PMID:24810617; http://dx.doi.org/ 10.1371/journal.pone.0095738
23. Luo K, Xiao Z, Ehrlich E, Yu Y, Liu B, Zheng S, Yu XF. Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc Natl Acad Sci U S A 2005; 102:11444-9;PMID:16076960; http://dx.doi.org/10.1073/pnas. 0502440102
24. Xiao Z, Ehrlich E, Yu Y, Luo K, Wang T, Tian C, Yu XF. Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology 2006; 349:290-9; PMID:16530799; http://dx.doi.org/10.1016/j.virol. 2006.02.002
25. Mehle A, Thomas ER, Rajendran KS, Gabuzda D. A zinc-binding region in Vif binds Cul5 and determines cullin selection. J Biol Chem 2006; 281:17259-65;PMID:16636053; http://dx.doi.org/10.1074/jbc. M602413200
26. Paul I, Cui J, Maynard EL. Zinc binding to the HCCH motif of HIV-1 virion infectivity factor induces a conformational change that mediates protein-protein interactions. Proc Natl Acad Sci U S A 2006; 103:18475- 80;PMID:17132731; http://dx.doi.org/10.1073/pnas.0604150103
27. Xiao Z, Ehrlich E, Luo K, Xiong Y, Yu XF. Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J 2007; 21:217-22; PMID:17135358; http:// dx.doi.org/10.1096/fj.06-6773com
28. Xiao Z, Xiong Y, Zhang W, Tan L, Ehrlich E, Guo D, Yu XF. Characterization of a novel Cullin5 binding domain in HIV-1 Vif. J Mol Biol 2007; 373:541-50;PMID:17869271; http://dx.doi.org/10.1016/j. jmb.2007.07.029
29. Evans SL, Schon A, Gao Q, Han X, Zhou X, Freire E, Yu XF. HIV-1 Vif N-terminal Motif is required for recruitment of Cul5 to Suppress APOBEC 3. Retrovirology 2014; 11:4; PMID:24422669; http://dx.doi. org/10.1186/1742-4690-11-4
30. Giri K, Maynard EL. Conformational analysis of a peptide approximating the HCCH motif in HIV-1 Vif. Biopolymers 2009; 92:417-25;19382167; http://dx.doi.org/10.1002/bip.21209
31. Giri K, Scott RA, Maynard EL. Molecular structure and biochemical properties of the HCCH-Zn2C site in HIV-1 Vif. Biochemistry 2009; 48:7969-78;PMID:19588889; http://dx.doi.org/10.1021/bi900677w
32. He Z, Zhang W, Chen G, Xu R, Yu XF. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J Mol Biol2008; 381:1000-11; PMID:18619467; http://dx.doi. org/10.1016/j.jmb.2008.06.061
33. Pery E, Rajendran KS, Brazier AJ, Gabuzda D. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. J Virol 2009; 83:2374-81;PMID:19109396; http://dx.doi.org/ 10.1128/JVI.01898-08
34. Chen G, He Z,Wang T, Xu R, Yu XF. A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. J Virol 2009; 83:8674-82; PMID:19535450; http://dx.doi.org/10.1128/JVI.00653-09
35. Tian C, Yu X, Zhang W, Wang T, Xu R, Yu XF. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J Virol 2006; 80:3112-5; PMID:16501124; http://dx.doi.org/10.1128/JVI.80.6.3112-3115.2006
36. Russell RA, Pathak VK. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol 2007; 81:8201-10; PMID:17522216; http://dx.doi.org/10.1128/JVI. 00395-07
37. OhAinle M, Kerns JA, Li MM, Malik HS, Emerman M. Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe 2008; 4:249-59, PMID:18779051; http://dx.doi.org/ 10.1016/j.chom.2008.07.005
38. Harari A, Ooms M, Mulder LC, Simon V. Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J virol 2009; 83:295- 303 PMID:18945781; http://dx.doi.org/10.1128/ JVI.01665- 0839.
39. Tan L, Sarkis PT, Wang T, Tian C, Yu XF. Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV- 1. FASEB J 2009; 23:279-87; PMID:18827027; http://dx.doi.org/10.1096/fj.07-088781
40. Ooms M, Brayton B, Letko M, Maio SM, Pilcher CD, Hecht FM, Barbour JD, Simon V. HIV-1 Vif adaptation to human APOBEC3H haplotypes. Cell Host Microbe 2013; 14:411-21; PMID:24139399; http:// dx.doi.org/10.1016/j.chom.2013.09.006
41. Binka M, Ooms M, Steward M, Simon V. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H. J Virol 2012; 86:49-59;PMID:22013041; http://dx.doi.org/ 10.1128/JVI.06082-11
42. Ooms M, Letko M, Binka M, Simon V. The resistance of human APOBEC3H to HIV-1 NL4-3 molcular clone is determined by a single amino acid in Vif. PloS One 2013; 8:e57744; PMID:23469063; http://dx.doi. org/10.1371/journal.pone.0057744
43. Sakai K, Dimas J, Lenardo MJ. The Vif and Vpr accessory proteins independently cause HIV-1-induced T cell cytopathicity and cell cycle arrest. Proc Natl Acad Sci 2006; 103:3369-74; http://dx.doi.org/10.1073/ pnas.0509417103
44. Wang J, Shackelford JM, Casella CR, Shivers DK, Rapaport EL, Liu B, Yu XF, Finkel TH. The Vif accessory protein alters the cell cycle of human immunodeficiency virus type 1 infected cells. Virology 2007; 359:243-52; PMID:17056089; http://dx.doi.org/10.1016/j.virol.2006.09.026
45. Izumi T, Io K, Matsui M, Shirakawa K, Shinohara M, Nagai Y, Kawahara M, Kobayashi M, Kondoh H, Misawa N, et al. HIV-1 viral infectivity factor interacts with TP53 to induce G2 cell cycle arrest and positively regulate viral replication. Proc Natl Acad Sci U S A2010; 107:20798-803; PMID:21071676; http://dx. doi.org/10.1073/pnas.1008076107
46. Zhen A, Wang T, Zhao K, Xiong Y, Yu XF. A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity. J Virol 2010; 84:1902-11; PMID:19939923; http://dx.doi.org/ 10.1128/JVI.01509-09
47. Zhen A, Du J, Zhou X, Xiong Y, Yu XF. Reduced APOBEC3H variant anti-viral activities are associated with altered RNA binding activities. PloS One 2012; 7: e38771; PMID:22859935; http://dx.doi.org/10.1371/ journal.pone.0038771
48. Wang J, Reuschel EL, Shackelford JM, Jeang L, Shivers DK, Diehl JA, Yu XF, Finkel TH. HIV-1 Vif promotes the G(1)- to S-phase cell-cycle transition. Blood 2011; 117:1260-9; PMID:21149631; http://dx.doi.org/ 10.1182/blood-2010-06-289215
49. Wang J, Shackelford JM, Selliah N, Shivers DK, O’Neill E, Garcia JV, Muthumani K, Weiner D, Yu XF, Gabuzda D, et al. The HIV-1 Vif Protein Mediates Degradation of Vpr and Reduces Vpr-Induced Cell Cycle Arrest. DNA Cell Biol 2008; 27:267-77; PMID:18462066; http://dx.doi.org/10.1089/ dna.2007.0707
50. Jager S, Kim DY, Hultquist JF, Shindo K, Larue RS, Kwon E, Li M, Anderson BD, Yen L, Stanley D, et al. Vif hijacks CBF-b to degrade APOBEC3G and promote HIV-1 infection. Nature 2012; 481:371-5; PMID:22190037; http://dx.doi.org/10.1038/nature10693
51. Hultquist JF, BinkaM, Larue RS, Simon V, Harris RS. Vif proteins of human and simian immunodeficiency viruses require cellular CBFbeta to degrade APOBEC3 restriction factors. J Virol 2012; 86:2874-7; PMID:22205746; http:// dx.doi.org/10.1128/JVI.06950-11